Margaret McGlynn - Vertex Pharmaceutic Independent Director


USD 281.79  1.44  0.51%   

Ms. Margaret G. McGlynn is Independent Director of Vertex Pharmaceuticals Incorporated. Ms. McGlynn retired from Merck Co. in 2009, where she served as President, Vaccines and Infectious Diseases and as President, Hospital and Specialty Products. During her 26 year career at Merck, she also held various leadership roles in the U.S. and globally in marketing, sales, managed care and business development. Following her retirement, Ms. McGlynn served as the President and Chief Executive Officer of the International AIDS Vaccine Initiative, a global notforprofit organization whose mission is to ensure the development of safe, effective and accessible HIV vaccines for use throughout the world, from 2011 until 2015. Ms. McGlynn serves as a member of the Board of Directors for Air Products and Chemicals, Inc., a company specializing in gases and chemicals for industrial uses, and Amicus Therapeutics, Inc., a biopharmaceutical company. She is also a member of the National Industrial Advisory Committee at the University at Buffalo School of Pharmacy and Pharmaceutical Sciences
Age: 58  Director Since 2011  MBA    
617 341-6100
McGlynn holds a B.S. in Pharmacy and an M.B.A. in Marketing from the State University of New York at Buffalo.

Margaret McGlynn Latest Insider Activity

Tracking and analyzing the buying and selling activities of Margaret McGlynn against Vertex Pharmaceutic stock is an integral part of due diligence when investing in Vertex Pharmaceutic. Margaret McGlynn insider activity provides valuable insight into whether Vertex Pharmaceutic is net buyers or sellers over its current business cycle. Note, Vertex Pharmaceutic insiders must abide by specific rules, including filing SEC forms every time they buy or sell Vertex Pharmaceutic'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Vertex Pharmaceutic Management Efficiency

Vertex Pharmaceutic has return on total asset (ROA) of 13.79 % which means that it generated profit of $13.79 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 24.93 %, meaning that it created $24.93 on every $100 dollars invested by stockholders. Vertex Pharmaceutic management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. Vertex Pharmaceutic Return on Investment is fairly stable at the moment as compared to the past year. Vertex Pharmaceutic reported Return on Investment of 28.05 in 2021. Return on Average Assets is likely to rise to 20.07 in 2022, whereas Return on Invested Capital is likely to drop (0.008739)  in 2022. Vertex Pharmaceutic Total Assets are fairly stable at the moment as compared to the past year. Vertex Pharmaceutic reported Total Assets of 13.43 Billion in 2021. Current Assets is likely to rise to about 10.3 B in 2022, whereas Revenue to Assets are likely to drop 0.50 in 2022.
The company currently holds 967.4 M in liabilities with Debt to Equity (D/E) ratio of 0.1, which may suggest the company is not taking enough advantage from borrowing. Vertex Pharmaceutic has a current ratio of 4.37, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Vertex Pharmaceutic until it has trouble settling it off, either with new capital or with free cash flow. So, Vertex Pharmaceutic's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Vertex Pharmaceutic sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Vertex to invest in growth at high rates of return. When we think about Vertex Pharmaceutic's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives


Walter McNerneyInternational Business Machines
Charles GiffordBank Of America
Bob TepperAllena Pharmaceuticals
Martha PollackInternational Business Machines
Alain BeldaInternational Business Machines
James OwensAlcoa Corp
David FarrInternational Business Machines
Robert YostBank Of America
Kevin LoftonGilead Sciences
Frederick McNabbInternational Business Machines
Michelle HowardInternational Business Machines
Roderick McGearyCisco Systems
Jack BovenderBank Of America
John ChildsBiohaven Pharmaceutical Holding
Stephen SangerPfizer Inc
Kristina JohnsonCisco Systems
James QuinceyPfizer Inc
Alfred ZollarInternational Business Machines
Stanley ONealAlcoa Corp
Shirley JacksonInternational Business Machines
Kelly KramerGilead Sciences
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 00 people. Vertex Pharmaceutic (VRTX) is traded on NASDAQ Exchange in USA and employs 3,900 people.

Vertex Pharmaceutic Leadership Team

Elected by the shareholders, the Vertex Pharmaceutic's board of directors comprises two types of representatives: Vertex Pharmaceutic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vertex. The board's role is to monitor Vertex Pharmaceutic's management team and ensure that shareholders' interests are well served. Vertex Pharmaceutic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vertex Pharmaceutic's outside directors are responsible for providing unbiased perspectives on the board's policies.
William Young, Independent Director
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Michael Parini, Executive Vice President and Chief Legal Officer
Alan Garber, Independent Director
Joshua Boger, Executive Director and Chairman of Science and Technology Committee
John Gray, Senior Vice President Genetic Therapies
Margaret McGlynn, Independent Director
Sangeeta Bhatia, Director
Terrence Kearney, Independent Director
Ian Smith, CFO, Executive Vice President
Paul Silva, Senior Vice President Corporate Controller
David Altshuler, Independent Director
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development
Elaine Ullian, Co-Lead Independent Director
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value
David Greenway, Director
Charles Wagner, CFO, Executive Vice President
Bruce Sachs, Co-Lead Independent Director
Lloyd Carney, Independent Director
Michael Partridge, Vice President - Investor Relations
Yuchun Lee, Independent Director
Kimberly White, Senior Vice President and Chief Communications Officer
Stuart Arbuckle, Chief Commercial Officer and Executive VP
Thomas Graney, CFO, Senior Vice President
Charles Milstein, Executive Vice President Chief Legal and Administrative Officer
Jeffrey Leiden, Chairman of the Board and Presidentident, CEO

Vertex Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vertex Pharmaceutic a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Vertex Pharmaceutic Investors Sentiment

The influence of Vertex Pharmaceutic's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Vertex. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Vertex Pharmaceutic Implied Volatility

Vertex Pharmaceutic's implied volatility exposes the market's sentiment of Vertex Pharmaceutic stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Vertex Pharmaceutic's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Vertex Pharmaceutic stock will not fluctuate a lot when Vertex Pharmaceutic's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Vertex Pharmaceutic in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Vertex Pharmaceutic's short interest history, or implied volatility extrapolated from Vertex Pharmaceutic options trading.

Current Sentiment - VRTX

Vertex Pharmaceutic Investor Sentiment

Most of Macroaxis users are at this time bullish on Vertex Pharmaceutic. What is your outlook on investing in Vertex Pharmaceutic? Are you bullish or bearish?
98% Bullish
2% Bearish

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Also, please take a look at World Market Map. Note that the Vertex Pharmaceutic information on this page should be used as a complementary analysis to other Vertex Pharmaceutic's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Complementary Tools for Vertex Stock analysis

When running Vertex Pharmaceutic price analysis, check to measure Vertex Pharmaceutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceutic is operating at the current time. Most of Vertex Pharmaceutic's value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceutic's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Vertex Pharmaceutic's price. Additionally, you may evaluate how the addition of Vertex Pharmaceutic to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Is Vertex Pharmaceutic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceutic. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
Market Capitalization
70.6 B
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Vertex Pharmaceutic is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceutic's value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceutic's market value can be influenced by many factors that don't directly affect Vertex Pharmaceutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceutic's value and its price as these two are different measures arrived at by different means. Investors typically determine Vertex Pharmaceutic value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.